Providing due diligence on a pain in-licensing opportunity


A European pharma company needed to conduct an expert reality check on a pain in-licensing opportunity.


We reviewed the clinical evidence generated by the biotech company in order to develop a picture of the commercial prospects for the proposed target product profile. We concluded that the product profile was commercially attractive, but given the underlying mechanisms of the drug and the data generated to date, it was highly unlikely that the product would provide the level of safety, efficacy and value that was proposed.

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch